Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

NCT05798156 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: Glofitamab
DRUG: Rituximab
DRUG: Obinutuzumab
DRUG: Polatuzumab vedotin

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]